Business
Potential role of invasive cellular protrusions
Potential role of invasive cellular protrusions.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n \n \n 14 June 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n \n \n PARSORTIX STUDY SHOWS POTENTIAL\n \n \n ROLE OF INVASIVE CELLULAR PROTRUSIONS IN THE FORMATION OF PROSTATE CANCER CTCs\n \n \n \n \n \n \n \n \n \n Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development\n \n \n \n \n \n \n \n \n \n Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,\n is pleased to announce that researchers at King's College London, UK, have published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells (CTCs). This novel finding has the potential to provide a new target, within the metastatic process, for the development of novel therapeutics in the prostate cancer setting.\n \n \n \n \n \n Invasive cellular protrusions are thought to be involved in degradation of the extracellular matrix (ECM), driving tumour invasion and metastasis. Formation of invasive cellular protrusions has been seen in many metastatic cancer cell lines, but there has previously been little evidence in prostate cancer cell lines. Firstly, the authors of this study have identified prostate cancer cell lines that form spontaneous invasive cellular protrusions in vitro, and show metastatic behaviour in vivo, proving to be a valid model for future studies.\n \n \n \n \n \n In addition, the researchers used ANGLE's marker-independent Parsortix\n \n ®\n \n system to isolate CTCs from prostate cancer patients with a Gleason score ≥7 (medium to high grade cancer). CTCs were identified in 16 out of 17 patients, with 8 patients having 10 or more CTCs. Overall, 75% of patients showed evidence of ECM degradation near the CTCs, and 40% of patients had invasive cellular protrusion presence aligning with ECM degradation. The authors speculate that prostate cancer cells detaching from the primary tumour may use t...